Daniel Feldman, MD
Chronic thrombocytopenia (CTP) has been shown to be a predictor of bleeding following transcatheter aortic valve replacement (TAVR). Managing peri-procedural anticoagulation can be difficult in this population because of the increased risk of bleeding. This analysis aims to evaluate the effect of CTP on clinical outcomes following TAVR and the interaction between CTP and periprocedural anticoagulation.